Core Insights - BD and ChemoGLO™ have formed a strategic collaboration to enhance hazardous drug contamination testing in healthcare settings, aiming to improve the safety of healthcare workers [1][2]. Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery, with over 70,000 employees and a presence in nearly every country [4]. - ChemoGLO™ specializes in hazardous drug detection and management solutions, providing accurate measurements of surface contamination levels for over 20 years [5][6]. Collaboration Details - The collaboration combines BD's HD Check System, which provides rapid qualitative results in 10 minutes, with ChemoGLO™'s LC-MS/MS analysis, delivering comprehensive quantitative reports on hazardous drugs within three to five days [2]. - This dual approach allows healthcare facilities to quickly identify contamination and gain deeper insights into exposure risks, reinforcing the commitment to healthcare worker safety [2][3]. Testing Workflow - The partnership offers a streamlined sampling and testing workflow, enabling healthcare facilities to monitor contamination effectively and take timely actions to protect workers [2]. - The combined testing approach aligns with recommendations from a 2020 consensus conference on hazardous drug surface contamination, advocating for both qualitative and quantitative testing to enhance environmental safety [2].